Marché mondial de la thromboembolie veineuse – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché de la thrombophilie veineuse

Le marché mondial de la thromboembolie veineuse devrait connaître une croissance significative au cours de la période de prévision. Les maladies cardiovasculaires (MCV) et le cancer sont de plus en plus répandus en raison de l'adoption du tabagisme, de l'augmentation du taux d'obésité, de l'alcool, du manque d'activité physique et de la consommation d'aliments riches en cholestérol . Le segment de la thrombose veineuse profonde devrait représenter plus des 3/5 des ventes de traitements de la thromboembolie veineuse d'ici 2022. Le COVID-19 a également eu un impact majeur sur la croissance du marché.

Data Bridge Market Research analyse le taux de croissance du marché mondial de la thromboembolie veineuse au cours de la période de prévision 2022-2029. Le TCAC attendu du marché mondial de la thromboembolie veineuse a tendance à être d'environ 8,50 % au cours de la période de prévision mentionnée. Le marché était évalué à 950 millions USD en 2021 et devrait atteindre 1 824,57 millions USD d'ici 2029. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Définition du marché

La thromboembolie veineuse est un type de pathologie dans lequel un caillot sanguin se forme le plus souvent dans les veines profondes de la jambe, de l'aine ou du bras et se déplace dans la circulation sanguine pour se loger dans les poumons. La thrombose veineuse profonde et l'embolie pulmonaire forment ensemble une thromboembolie veineuse, une pathologie médicale dangereuse et potentiellement mortelle. Elle revêt une grande importance pour le secteur de la santé et devrait donc connaître une forte augmentation au cours de la période de prévision.

Portée et segmentation du marché de la thrombophilie veineuse

Global Thrombophilia Market Dynamics

Drivers

• Increase in Geriatric Population

The geriatric population is expected to increase the patient population globally, which boots the global venous thromboembolism market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. This boost the market growth.

• Rising Awareness Towards The Disease

Numerous organizations are taking initiatives to raise awareness about VTE worldwide. Few organizations, in collaboration with the CDC, are joining the ‘Stop the Clot, Spread the Word’ campaign to spread awareness all over the country about blood clots. Many such initiatives will positively impact knowledge about disease diagnosis and treatment alternatives, thus boosting the market value during the forecast period.

Opportunities

• Growing Number of Orthopedic Procedures

Growing number of surgical procedures has encouraged the adoption of compression devices for DVT prophylaxis. Surgeries that include orthopedic procedures cause long immobility and thus, there is a greater probability of DVT development. Therefore, patients are recommended to use compression devices post-procedure to limit the risk. Thus, this will create more opportunities for the market growth.

• Emergence of Several Treatment Methods

Venous thromboembolism is a potentially dangerous condition and if it is not treated at suitable time, it may lead to complications and death. According to Centres for Disease Control and Prevention (CDC), about 60,000-100,000 people in the U.S. die due to venous thromboembolism. Also, blood clots are mainly managed by drug therapy. Although, sometimes, patient may require surgical intervention and mechanical devices to manage and treat the condition more successfully. Thus, with key market players introducing novel devices, the end-users will have wider range of treatment options, thus presenting huge growth opportunities during the forecast period. This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global venous thromboembolism market over a forecast period.

• High Cost

The huge expenditure of the treatment methods such as different anti-thrombotic medications, thrombolytic therapy hamper the market growth.

This global venous thromboembolism market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global venous thromboembolism market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In May 2019, Pfizer, Inc. received the U.S. FDA approval for FRAGMIN, which is a dalteparin sodium to lessen the recurrence of venous thromboembolism (VTE) in pediatric patients, aged 1 month and above.
• In July 2019, Bayer AG and Johnson and Johnson’s JNJ subsidiary announced novel results from phase III EINSTEIN-Jr study about children suffering from venous thromboembolism (VTE).
• In June 2021, Janssen Pharmaceuticals, Inc, announced receiving Food and Drug Administration approval for its latest products XARELTO (rivaroxaban) for the treatment of two indications: deep venous thrombosis and pulmonary embolism. This will support the company to strengthen its footprint in the market.

Global Venous Thromboembolism Market Scope

The global venous thromboembolism market is segmented on the basis of type, drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Non-Segmented Pneumatic Compression Pumps
• Segmented Pneumatic Compression Pumps without Gradient
• Segmented Pneumatic Compression Pumps with Calibrated Gradient
• Upper Pneumatic Compression Sleeves
• Lower Pneumatic Compression Sleeves
• Permanent Inferior Vena Cava Filters
• Retrievable Inferior Vena Cava Filters
• Embolectomy Balloon Catheters
• Percutaneous Thrombectomy Devices
• Catheter-Directed Thrombolysis (CDT) Devices

Type

• Deep Vein Thrombosis
• Pulmonary Embolism
• Others

Treatment

• Anti-Clotting Medications
•  Mechanical Devices
• Thrombolytic Therapy
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Venous Thromboembolism Market Regional Analysis/Insights

The global venous thromboembolism market is analysed and market size insights and trends are provided by type, drugs, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global venous thromboembolism market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of key manufacture of the product and increased prevalence of thromboembolism in this region.

Asia-Pacific dominates the market due to increased prevalence of embolism and increasing geriatric population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Venous Thromboembolism Market Share Analysis

The global venous thromboembolism market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global venous thromboembolism market.

Key players operating in the global venous thromboembolism market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Aspen Holdings (États-Unis)
• Changzhaou Qianhong Bio-pharma Co., ltd. (Chine)
• Fresenius Kabi AG (Allemagne)
• Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (Chine)
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Novartis SA (Suisse)
• Janssen Global Services, LLC (États-Unis)

SKU-54413